Drug Trial Radar · NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,314
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
May 10, 2028
Study completion Dec 2, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
Interventions
OpevesostatDrug
Administered orally
DexamethasoneDrug
Administered orally
Fludrocortisone acetateDrug
Administered orally
HydrocortisoneDrug
Administered orally or IM as a rescue drug
Abiraterone acetateDrug
Administered orally
Prednisone acetateDrug
Administered orally
EnzalutamideDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 82 months
Locations
330 sites in 39 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center - North Campus ( Site 0073)
Tucson, Arizona · Recruiting
CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120)
Irvine, California · Recruiting
UCLA Hematology/Oncology - Santa Monica ( Site 0044)
Los Angeles, California · Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)
Orange, California · Recruiting
Stanford Cancer Center ( Site 0036)
Palo Alto, California · Recruiting
Emad Ibrahim,MD,INC. ( Site 0012)
Redlands, California · Completed
Kaiser Permanente Riverside Medical Center ( Site 0099)
Riverside, California · Recruiting
University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 0114)
Sacramento, California · Recruiting
San Francisco VA Health Care System ( Site 0093)
San Francisco, California · Recruiting
Kaiser Permanente-Kaiser Permanente, Vallejo Medical Center, Adult Oncology ( Site 0101)
Vallejo, California · Active not recruiting
University of Colorado Anschutz Medical Campus ( Site 0046)
Aurora, Colorado · Recruiting
UCHealth Highlands Ranch Hospital ( Site 0111)
Highlands Ranch, Colorado · Recruiting
Colorado Clinical Research ( Site 0067)
Lakewood, Colorado · Recruiting
University of Colorado Health - Lone Tree Medical Center ( Site 0112)
Lone Tree, Colorado · Recruiting
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
New Haven, Connecticut · Recruiting
MedStar Washington Hospital Center ( Site 0103)
Washington D.C., District of Columbia · Recruiting
Florida Cancer Specialists - South ( Site 7003)
Fort Myers, Florida · Active not recruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 0107)
Miami Beach, Florida · Recruiting
Memorial Hospital West-Memorial Cancer Institute ( Site 0109)
Pembroke Pines, Florida · Recruiting
Northside Hospital-Northside Hospital Oncology Network ( Site 0100)
Atlanta, Georgia · Recruiting
Edward-Elmhurst Healthcare, Elmhurst Hospital-Nancy W. Knowles Cancer Center ( Site 0074)
Elmhurst, Illinois · Completed
Edward-Elmhurst Healthcare, Edward Hospital-Edward Cancer Center ( Site 0075)
Naperville, Illinois · Completed
Illinois Cancer Care ( Site 0104)
Peoria, Illinois · Recruiting
Urology of Indiana - Carmel ( Site 0055)
Carmel, Indiana · Recruiting
University of Kentucky Chandler Medical Center ( Site 0048)
Lexington, Kentucky · Active not recruiting
Baltimore Veterans Affairs Medical Center ( Site 0069)
Baltimore, Maryland · Recruiting
Greenebaum Comprehensive Cancer Center ( Site 0049)
Baltimore, Maryland · Recruiting
Chesapeake Urology ( Site 0009)
Towson, Maryland · Recruiting
Henry Ford Hospital ( Site 0015)
Detroit, Michigan · Recruiting
Cancer and Hematology Centers of Western Michigan ( Site 0005)
Grand Rapids, Michigan · Recruiting
Avera Cancer Institute - Marshall ( Site 0122)
Marshall, Minnesota · Recruiting
HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072)
Saint Louis Park, Minnesota · Recruiting
HealthPartners Cancer Research Center-HealthPartners Cancer Center at Regions Hospital ( Site 0092)
Saint Paul, Minnesota · Recruiting
St. Vincent Frontier Cancer Center-Research ( Site 0037)
Billings, Montana · Recruiting
Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026)
Omaha, Nebraska · Recruiting
OptumCare Cancer Care-Research Department ( Site 0078)
Las Vegas, Nevada · Recruiting
Comprehensive Cancer Centers of Nevada ( Site 0010)
Las Vegas, Nevada · Recruiting
Rutgers Cancer Institute of New Jersey ( Site 0033)
New Brunswick, New Jersey · Recruiting
Associated Medical Professionals - Urology ( Site 0081)
Syracuse, New York · Recruiting
University Hospitals Cleveland Medical Center ( Site 0043)
Cleveland, Ohio · Recruiting
Showing 40 of 330 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.